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The present study investigates the association of
mutations in the nuclear receptor NR4A2 in
schizophrenic patients. The human Nur-related
receptor 1, NR4A2, is an orphan nuclear receptor
that can be constitutively active as a transcription
factor and for which no natural ligand has yet
been identified. Alone or with retinoid X receptor,
RXR, NR4A2 influences the expression of several
genes important for human brain development
and regulation. In the absence of Nurr1 (the
mouse homologue to human NR4A2), ventral
mesencephalic dopaminergic mouse neurons evi-
dence severe developmental failure, a condition
that is lethal soon after birth. Nurr1 involvement
in the dopaminergic system makes it a good
candidate for study in neuropsychiatric disorders
such as schizophrenia and Parkinson disease.
Evidence by others support this hypothesis
(1) mapping of the NR4A2 gene to chromosome
2q22-23, a region with suggestive linkage to
schizophrenia and (2) identification of mutations
in patients with schizophrenia (c.366-369delTAC,
c.308A>G, c.-469delG), manic depression (c.289A>
G), and familial Parkinson’s disease (c.-291delT, c.-
245T>G). To further extend these observations,
we searched for all these mutations in 176 Cauca-
sian Portuguese and 82 Caucasian Brazilian sub-
jects with lifetime diagnosis of schizophrenia. The
study failed to identify any of the described
mutations in patients or controls. Nevertheless,
these negative results do not exclude altered
expression of nuclear receptors in schizophrenia
or the presence of other mutations.
 2004 Wiley-Liss, Inc.
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INTRODUCTION
Schizophrenia is a chronic psychotic disorder of unknown
etiology. Twin and family studies demonstrate a genetic basis
for the disease [Tsuang et al., 2001]. Several genome wide
studies identified chromosome loci consistently linked to
increased susceptibility to schizophrenia in different popula-
tions [Lewis et al., 2003]. Despite the evidence for genetic
predisposition, the lack of concordance in monozygotic twins
implies that an epigenetic environmental effect is required
for disease onset [Tsuang et al., 2001]. For this reason, interest
has been raised in hypothesis bridging both genetic and
environment-related mechanisms. Environmental factors such
as hormones and vitamins interact with different nuclear
receptors and interfere with the transcription of several genes
on a developmental regulated fashion. Among these are the
retinoids, considered good candidates because of genetic
linkage studies implicating schizophrenia with disregulation
of the retinoid cascade and/or genes whose expression they
regulate [Goodman, 1998]. The genes for dopamine-2 receptor,
synapsin, and dopamine b-hydroxylase are among thosewhose
expression requires activation by retinoids [Samad et al., 1997;
Kim et al., 2001, 2003; Balmer and Blomhoff, 2002]. Pharma-
cological, histological, and brain imaging data have for long
implicated dopaminergic dysfunction in the etiology of schizo-
phrenia. Retinoid availability can, therefore, interfere with
susceptibility to schizophrenia, either directly, through the
dopamine system, or indirectly through molecules involved in
its development and/or regulation. Interestingly, retinoid
analogs have been suggested in the treatment of schizophre-
nia, alone or in combination with dopamine receptor agonists
[Citver et al., 2002].
Retinoic acid receptors belong to the steroid/thyroid hor-
mone nuclear receptor superfamily that includes several
orphan receptors for which no ligands have been identified.
These receptors often act as heterodimers greatly increasing
the complexity of gene regulation. NR4A2, one of these orphan
nuclear receptors, is known to regulate transcription of target
genes in two different ways: alone, as a monomer, or as a
partner with the retinoid X receptor (RXR) [Perlmann and
Jansson, 1995; Wang et al., 2003].
Nurr1 (themouse homologue to humanNR4A2 gene)mRNA
is expressed very early in the ventral midbrain [Zetterstro¨m
et al., 1996, 1997] and disruption of its expression is respon-
sible for massive failure to generate dopaminergic neurons in
the midbrain and causes death soon after birth [Zetterstro¨m
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et al., 1997; Saucedo-Cardenas et al., 1998]. The lack of
dopaminergic neurons in themidbrain seems to be relatedwith
the inability to express tyrosine hydroxylase, the rate-limiting
enzyme in dopamine synthesis [Zetterstro¨m et al., 1996].
Furthermore, Nurr 1 seems to retain its role in mature dopa-
minergic neurons, since its expression continues over adult-
hood and is extremely impaired after ventral mesencephalic
dopaminergic neurons injury [Zetterstro¨m et al., 1996].
These observations increased the interest in identifying
precise molecular and biochemical mechanisms of behavior
regulation by NR4A2 in psychiatric and neurological dis-
orders. Furthermore, the 2q22-q23 chromosome region that
harbors the NR4A2 gene has suggestive linkage with schizo-
phrenia in various populations [Moises et al., 1995; Williams
et al., 1999; DeLisi et al., 2002; Lewis et al., 2003]. In
accordance to this hypothesis several groups have looked for
mutations in the NR4A2 human gene that could increase
susceptibility to schizophrenia. Up to date, two deletions and
one missense mutation have been described in schizophrenic
patients and one missense mutation has been found in manic-
depressed individuals [Buervenich et al., 2000; Chen et al.,
2001] while, recently, two mutations in the untranslated
region have been identified in patients with familial Parkin-
son’s disease [Le et al., 2003]. These findings prompted us to
investigate all these NR4A2 mutations in a large sample of
Portuguese and Brazilian schizophrenic patients. Patients
fulfilledDSMIV lifetime diagnosis of schizophrenia, confirmed
by Operational Checklist for Psychotic Disorders (OPCRIT)
diagnostic algorithm. None of the mutations described in the
literature were identified in this group of patients.
MATERIALS AND METHODS
The sample consisted in 176 Portuguese (age range 15–74,
average 34.0; 67 female and 109 male) and 82 Brazilian
(age range 18–63, average 34.3; 10 female and 72 male)
schizophrenic patients and 105 Portuguese (age range 19–79,
average 35.5; 53 female and 52 male) and 85 Brazilian
(age range 19–58, average 32.9; all men) mentally healthy
individuals. All subjects were unrelated Caucasians. Patients
gave informed consent for the study, and ethic committees of
both institutions approved the study. All patients (Portuguese
and Brazilian) were classified by the OPCRIT system
[McGuffin and Farmer, 2001]. OPCRIT automated system
gathered information from all case records, including medical,
nursing, social work and occupational therapy notes together
with data from clinical interview with patient and relatives.
Additionally, Portuguese schizophrenic patients received life-
time diagnosis using DIGS (Diagnostic Interview for Genetic
Studies) as previously described [Nurnberger et al., 1994].
Controls were from European origin or descent and free of any
lifetime diagnosis of major mental illness and physical illness.
Portuguese controls received DIGS assessment and Brazilian
controls were selected among blood bank volunteer donors
documented to be free of chemical dependence [Rios et al.,
2003]. All interviews and diagnostic formulations were
performed by one of the authors. Venous blood was drawn
from all subjects and DNA extracted using standard salting-
out procedures.
For genotyping the c.-245T>G, c.289 A>G, c.308 A>G
mutations and the deletion c.-469delG, we followed PCR
conditions previously described [Buervenich et al., 2000; Chen
et al., 2001; Le et al., 2003]. PCR products were analyzed on gel
electrophoresis after digestion with the restriction enzymes
Ava II (Fermentas, Vilnius, Lithuania), ApaL I (Fermentas),
Tse I (New England BioLabs, Beverly, MA), and Cfr I
(Fermentas), respectively. The c.366-369delTAC deletion
was screened by single strand conformation polymorphism
(SSCP) on the PCR product amplified with the primers (50-30)
CTTGTACCAAATGCCCCTGT and GAGACTGGCGTTTT-
CCTCT. Electrophoresis on 10% non-denaturing polyacryla-
mide gel with 2.5% glycerol was performed at 500 V for 2.5–3
hr. Temperature was strictly maintained at 148C. Samples
from patient carriers of the mutations c.366-369delTAC, c.289
A>G, and c.308 A>G were used as controls.
Search for the c.-291delT on the PCR product amplified with
primers previously described [Le et al., 2003] was done by
SSCP analysis on MDE gel (Cambrex Bio Science Rockland,
Rockland, ME) run at 4, 10, or 258C.
RESULTS
Using SSCP analysis, we searched the deletions c.366-
369delTAC and c.-291delT, looking also for other possible
mutations [Vidal-Puig and Moller, 1994] on the same PCR
product. Figure 1 shows the SSCPmigration pattern of a c.366-
369delTAC deletion carrier. None of the sample tested
revealed the presence of mutated alleles.
For the c.-291delTdeletionweanalyzed one subpopulation of
60 Portuguese schizophrenic patients and run the SSCP at
three different temperatures to increase the rate of detection.
Again, we failed to identify any mutation in the PCR product
containing the position c.-291. Analysis of the mutations c.-
469delG, c.-245T>G, c.289A>G, and c.308A>Gwas done by
digestion with the enzymes Cfr I, Ava II, ApaL I, and Tse I for
which a new restriction site is present in the mutated allele.
None of the samples, from schizophrenic or mentally healthy
individuals, contained any of the mutations screened.
Table I is a summary of all studies, including ours, in
which NR4A2 mutations described in diseases have been
investigated.
DISCUSSION
In the present study we investigated, for the first time, the
presence of two NR4A2 mutations recently identified in
familial Parkinson’s disease [Le et al., 2003] in 258 schizo-
phrenic patients and 190 mentally healthy individuals. We
also searched for mutations in the NR4A2 previously describ-
ed in patients with schizophrenia and manic-depression
[Buervenich et al., 2000; Chen et al., 2001]. No mutation was
found either in patients or controls. Given the complex etiology
of schizophrenia and the failure to identify a single causative
gene, it is unlikely that any individual mutation will be
strongly represented in the patient’s population [Chakravarti,
1999]. In the case of transcription factors such as nuclear
receptors, several different mutations can impair proper
function and influence the appropriate expression of several
genes. Therefore, for any newmutation found it is important to
increase the size of the patient sample analyzed. The fact that
Fig. 1. Single strand conformation polymorphism (SSCP) analysis of the
NR4A2 exon 3 PCR fragment. On lane 8 run a sample containing the c.366-
369delTAC mutation. Lanes 1–6 correspond to Brazilian schizophrenic
patients and lanes 7, 9–15 to Brazilian mentally healthy individuals.
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we failed to identify the mutations previously described
confirms that they are very rare in NR4A2 gene.
Other studies have reported lack of association of NR4A2
polymorphic variants in the promoter [Carmine et al., 2003],
50and 30 untranslated regions and intron 6 with schizophrenia
[Ishiguro et al., 2002; Iwayama-Shigeno et al., 2003].
The human NR4A2 gene exists as a single locus in human
genome, covering 8.3 Kb in length, consisting of eight exons
and is mapped to chromosome 2q22-23 [Ichinose et al., 1999;
Torii et al., 1999]. This chromosome regionhas been implicated
in schizophrenia [Lewis et al., 2003]. The mutations
c.289A>G, c.308A>G,and c.366-369delTAC, originate amino
acid changes at the protein level (M97V, H103R, and DY122,
respectively) and result in decreased in vitro transcriptional
activity of NR4A2 dimmers [Buervenich et al., 2000].
Decreased transcription activity of theNR4A2 is also described
for the mutations in the 50 untranslated region found in
patients with Parkinson’s disease [Le et al., 2003]. Therefore,
impaired transcription activation of downstream target genes
such as tyrosine hydroxylase is expected in carriers of these
mutant variants of NR4A2.
Studies in mice have revealed important functions for
NR4A2 that clearly suggest its possible involvement in several
disorders of the central nervous system in which the dopami-
nergic systemhas been implicated.Observations inNurr1-null
mice revealed that Nurr1 is requested for the formation of
midbrain dopaminergic neurons [Zetterstro¨m et al., 1997;
Saucedo-Cardenas et al., 1998] and that tyrosine hydroxylase,
the rate-limiting enzyme in the cathecolaminergic pathway, is
absent in dopaminergic neurons [Zetterstro¨m et al., 1997]. On
the other hand, mice lacking the D2 receptors for dopamine
show increase Nurr1 expression in mesencephalic dopaminer-
gic neurons, suggesting that actions mediated by D2 receptors
might be a consequence of altered expression of Nurr1 [Tseng
et al., 2000]. In addition, Nurr1 enhances the transcription of
the human dopamine transporter gene [Sacchetti et al., 2001],
one of the most specific phenotypic markers for dopaminergic
neurons, and of the tyrosinehydroxylase gene [Sakurada et al.,
1999; Kim et al., 2001, 2003]. Studies in Nurr1-null hetero-
zygousmice show thatNurr1 increases spontaneous locomotor
activity in response to stress [Eells et al., 2002]. The effect of
amphetamines in Nurr1-null heterozygous locomotion re-
mains controversial [Eells et al., 2002; Ba¨ckman et al., 2003].
These observations suggest that NR4A2 by itself, or through
heterodimerization partners, may participate in diseases
with altered dopaminergic function such as Parkinson’s,
TABLE I. NR4A2 Mutations Detected in Patients With Schizophrenia, Manic Depression, and Parkinson’s Disease
Mutation Location Population In vitro transcription activity
c.-469 delG Promoter 2/176 Han Chinese schizophrenic
[Chen et al., 2001]
Not determined
0/176 Caucasian Portuguese schizophrenic
0/82 Caucasian Brasillan schizophrenic
c.-291 delT Exon 1, untranslated 8/107 familial þ 0/94 sporadic Parkinson’s
(mostly Caucasian) [Le et al., 2003]
Decreased [Le et al., 2003]
0/60 Caucasian Portuguese schizophrenic
c.-245 T>G Exon 1, untranslated 2/107 familialþ0/94 sporadic Parkinson’s
(mostly Caucasian) [Le et al., 2003]
Decreased [Le et al., 2003]
0/176 Caucasian Portuguese schizophrenic
0/82 Caucasian Brasilian schizophrenic
c.289 A>G Exon 3, coding 0/135 Swedish schizophrenics
[Buervenich et al., 2000]
Decreased [Buervenich et al., 2000]
0/160 North American Caucasian
schizophrenics [Buervenich et al., 2000]
0/70 Caucasian Swedish idiopathic Parkinson
[Buervenich et al., 2000]
1/30 Caucasian Swedish manic depressed
[Buervenich et al., 2000]
0/176 Caucasian Portuguese schizophrenic
0/82 Caucasian Brasilian schizophrenic
c.308 A>G Exon 3, coding 1/135 Swedish schizophrenics
[Buervenich et al., 2000]
Decreased [Buervenich et al., 2000]
0/160 Caucasian North American
schizophrenics [Buervenich et al., 2000]
0/70 Caucasian Swedish Idiopathic Parkinson
[Buervenich et al., 2000]
0/30 Caucasian Swedish manic depressed
[Buervenich et al., 2000]
0/176 Caucasian Portuguese schizophrenic
0/82 Caucasian Brasilian schizophrenic
c.366-369 del TAC Exon 3, coding 1 childhood-onset/135 Caucasian Swedish
schizophrenics [Buervenich et al., 2000]
Decreased [Buervenich et al., 2000]
0/160 Caucasian North American
schizophrenics [Buervenich et al., 2000]
0/70 Caucasian Swedish Idiopathic Parkinson
[Buervenich et al., 2000]
0/30 Caucasian Swedish manic depressed
[Buervenich et al., 2000]
0/176 Caucasian Portuguese schizophrenic
0/82 Caucasian Brasilian schizophrenic
Represented is the number of individuals in which NR4A2 mutations were found among all patients tested.
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schizophrenia, and drug abuse. NR4A2may also be implicated
in some personality traits with increased vulnerability to
stress [Eells et al., 2002] such as those in the schizophrenia
phenotype spectrum. Bothmutations associated with decreas-
ed or increased NR4A2 activity and with altered regulation of
theNR4A2 gene throughout development might be associated
with disorders such as schizophrenia and Parkinson’s. Future
studies must address whether the expression of NR4A2 is
altered in the brain of schizophrenic patients or influences
their response to alcohol exposure or drug treatment. Better
understanding of the pathways involving NR4A2 might make
it a potential target for therapy with drugs like 6-mercapto-
purine analogs or even stem-cell transplants as recently sug-
gested [Ordentlich et al., 2003].
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